Leading the Way in Life Science Technologies

GEN Exclusives

More »

Feature Articles

More »
Mar 1, 2009 (Vol. 29, No. 5)

China Stays Committed to Biodevelopment

Country’s Life Science Companies Attract Investment Despite Global Economic Meltdown

  • Population Factor

    Looking on the bright side, Chinese domestic market demand for healthcare products and services will continue to grow as a result of the government’s strong mandate to provide healthcare to the country’s entire 1.3 billion population, including the 70% living in rural areas.

    “The large patient and talent pools, coupled with massive layoffs in the U.S. life science industry, makes China a highly attractive place for biopharmaceutical talents,” remarked Jonathan Wang, managing director at Orbimed, a private equity firm.

    Among the presenting companies and those who have achieved funding success, a common theme has emerged: many founders are “sea turtles” (overseas returnees), Chinese nationals who came to North America or Europe for graduate studies and subsequently gained industry or academic research experience, then returned to China as entrepreneurs.

    Some of them belong to the new class of “sea gulls” who commute back and forth between China and their second home overseas. Many have established a joint presence in China, where much of the service or discovery operation is ongoing, and in the U.S. (or Canada, Europe) where business development and other corporate functions are maintained.

Related content

Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »